Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2018
ASCO 2018
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
Med City News
Thu, 06/7/18 - 11:12 pm
CAR-T
bispecific antibodies
BIO 2018
ASCO 2018
How An Old Diabetes Drug Made A Big Splash At The Biggest Cancer Confab
Forbes
Thu, 06/7/18 - 09:48 am
ASCO 2018
lung cancer
type 2 diabetes
metformin
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
Thu, 06/7/18 - 09:35 am
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
ASCO18: Who were the big winners and losers?
Biopharma Dive
Wed, 06/6/18 - 04:06 pm
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
Endpoints
Tue, 06/5/18 - 12:09 pm
AbbVie
Rova-T
ASCO 2018
antibody-drug conjugate
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Fierce Pharma
Mon, 06/4/18 - 10:24 pm
Bristol-Myers Squibb
biomarkers
ASCO 2018
Opdivo
#ASCO18: Don’t write off IDO yet, says NewLink
Fierce Biotech
Mon, 06/4/18 - 10:19 pm
IDO inhibitors
NewLink Genetics
ASCO 2018
indoximod
ASCO18: Jounce plummets further on weak efficacy data
Biopharma Dive
Mon, 06/4/18 - 10:16 pm
Jounce Therapeutics
ASCO 2018
JTX-2011
solid tumors
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Mon, 06/4/18 - 10:09 pm
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today
Motley Fool
Mon, 06/4/18 - 09:55 pm
TG Therapeutics
umbralisib
chronic lymphocytic leukemia
ASCO 2018
ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught
Fierce Pharma
Mon, 06/4/18 - 12:09 pm
Merck
ASCO 2018
Keytruda
AstraZeneca
Eisai
ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2
Biopharma Dive
Mon, 06/4/18 - 09:37 am
AbbVie
Imbruvica
Venclexta
chronic lymphocytic leukemia
small lymphocytic lymphoma
ASCO 2018
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
Biopharma Dive
Mon, 06/4/18 - 09:34 am
Celgene
JCAR017
liso-cel
CAR-T
B-cell non-Hodgkin lymphoma
ASCO 2018
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Mon, 06/4/18 - 09:31 am
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
CP Wire
Mon, 06/4/18 - 09:18 am
Merck
Keytruda
small cell lung cancer
ASCO 2018
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
CP Wire
Mon, 06/4/18 - 09:16 am
Array Biopharma
encorafenib
binimetinib
advanced melanoma
ASCO 2018
#ASCO18: A Weekend of Surprises
Motley Fool
Sun, 06/3/18 - 09:13 pm
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
First Major Trial Of Keytruda For Prostate Cancer Shows It Works, But Only For A Minority Of Men
Forbes
Sun, 06/3/18 - 10:31 am
Merck
Keytruda
advanced prostate cancer
ASCO 2018
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Endpoints
Sun, 06/3/18 - 10:29 am
Roche
taselisib
fulvestrant
metastatic breast cancer
ASCO 2018
Many Breast Cancer Patients Can Safely Skip Chemo, Large Trial Confirms
Forbes
Sun, 06/3/18 - 10:27 am
early-stage breast cancer
breast cancer
chemotherapy
Oncotype DX
diagnostics
Genomics Health
ASCO 2018
Pages
1
2
next ›
last »